Form 4: Lantern Pharma Inc. Executive Kishor G. Bhatia Reports Stock Option Grant

Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc., reports the acquisition of stock options.

Summary

• On July 15, 2024, Kishor G. Bhatia, the Chief Scientific Officer of Lantern Pharma Inc., was granted stock options to purchase 35,000 shares of common stock.
• The exercise price of these options is $4.35 per share.
• The options vest in equal monthly increments over a 24-month period, starting August 15, 2024.
• The options expire on July 15, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting confidence in the company's future performance. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to attract and retain top talent.
• The vesting schedule of 24 months is also fairly typical, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the Chief Scientific Officer to drive innovation and company growth.
• Employees may view the grant as a positive sign of the company's commitment to its leadership team.

Key Dates